Who makes Topical High dose Capsaicin?

Topical High dose Capsaicin is developed by Medical University of Vienna.

What development phase is Topical High dose Capsaicin in?

Topical High dose Capsaicin is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Topical High dose Capsaicin

Medical University of Vienna · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Topical High dose Capsaicin
Also known as	Topical Capsaicin 8%, Qutenza® patch
Sponsor	Medical University of Vienna
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery (PHASE3)
Quantitative Ultrasound Response of Capsaicin (EARLY_PHASE1)
Sickle Cell Pain: Intervention With Capsaicin Exposure (PHASE1)
Pain Thresholds Under High-dose Topical Capsaicin (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Topical High dose Capsaicin CI brief — competitive landscape report
Topical High dose Capsaicin updates RSS · CI watch RSS
Medical University of Vienna portfolio CI